Company expects sustained quarter-over-quarter growth for KOMZIFTI.
Kura expects to expand physician adoption of KOMZIFTI across treatment centers.
Company anticipates cash resources sufficient to fund the ziftomenib AML program through topline Phase 3 results in 2028.
Key financial and analyst details
Metric
Actual
Q2 Net Loss
$68.33 million
Q2 Operating Expenses
$93.88 million
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell".
The average consensus recommendation for the biotechnology & medical research peer group is "buy".
Wall Street's median 12-month price target for Kura Oncology, Inc. is $28.00, about 182% above its August 11 closing price of $9.93.
Q2 revenue rose on KOMZIFTI uptake
U.S. cancer drugmaker's Q2 net product revenue rose 57% from prior quarter on KOMZIFTI uptake.
Total Q2 revenue grew year over year, driven by product and collaboration revenue.
Net loss widened to $68.3 million as R&D and SG&A expenses increased.
KURA•
